XXXX therapy and associated clinical outcomes in the MADIT-CRT trial.

@entity1 @entity712 @entity1165 @entity737 @entity6838 @entity2224 @entity204
BACKGROUND: @entity6838 's pharmacological, hemodynamic, and electrophysiological properties are well understood. However, in modern @entity712 ( @entity712 ) treatment, its effect has yet to be fully investigated. OBJECTIVE: The aim of the present study was to determine the effects of @entity6838 on outcomes in @entity1 with mild @entity712 implanted with an @entity737 ( @entity737 ) or cardiac resynchronization therapy with defibrillator (CRT-D) device. METHODS: We investigated the effect of @entity6838 treatment on the end points of @entity712 / @entity204 , @entity712 alone, @entity204 alone, and @entity1165 or @entity2224 (VT/VF) in 1820 @entity1 with mild @entity712 (New York Heart Association class I and II), prolonged QRS duration (>= 130 ms), and reduced left ventricular ejection fraction ( <=30%) enrolled in the Multicenter Automatic Defibrillator Implantation Trial - Cardiac Resynchronization Therapy trial. Multivariate Cox proportional hazards regression models were used to determine the effect of time-dependent @entity6838 usage on the end points. RESULTS: @entity6838 therapy was not associated with an increased or decreased risk of @entity712 / @entity204 (hazard ratio [HR] 1.07; 95% confidence interval [CI] 0.86-1.33; P = .0.56), @entity712 alone (HR 1.1.04; 95% CI 0.82-1.32; P = .76), or @entity204 alone (HR 0.93; 95% CI 0.67-1.32; P = .71). However, @entity6838 was associated with a significant 41% increased risk of VT/VF (HR 1.41; 95% CI 1.14-1.75; P = .002), which was driven by a significantly increased risk of VT/VF with heart rate >= 200 beats/min (HR 1.65; 95% CI 1.27-2.15; P  <= .001), whereas no increased risk of VT/VF with heart rate <200 beats/min was evident (HR 1.20; 95% CI 0.92-1.57; P = .19). No significant differences in @entity6838 's effect on any of the end points were found between @entity1 with @entity737 and @entity1 with CRT-D (interaction P > .5). CONCLUSION: The use of @entity6838 in @entity1 with mild @entity712 implanted with an @entity737 or CRT-D device was not associated with reductions in @entity712 / @entity204 events. However, @entity6838 therapy was associated with an increased risk of high-rate VT/VF (>= 200 beats/min).
